Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Lilly’s fourth-quarter estimates, the fourth quarter that we just finished ... I gotta tell you, however, I can’t think of a ...

All told, Lilly stock still gained 33% in 2024 ... Mounjaro and Zepbound. For the fourth quarter, Lilly calls for revenue of $3.5 billion for Mounjaro and $1.9 billion for Zepbound.

Results for the fourth quarter of 2024 should show revenue ... The problem, however, goes back to valuation. Eli Lilly is a stock which you might consider to be "priced to perfection" because ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...